JUBLPHARMA - Technical Analysis with Chart Patterns & Indicators

Last Updated Time : 20 Dec 25, 03:55 pm

Technical Rating: 3.0

📊 Chart Patterns & Trend: JUBLPHARMA is trading slightly below its 50 DMA (1,093 ₹) but above its 200 DMA (1,068 ₹), showing mixed signals. The price has corrected from its 52-week high (1,250 ₹) and is consolidating near support levels around 1,060–1,080 ₹.

📈 Moving Averages: Current price (1,073 ₹) is sandwiched between the 50 DMA and 200 DMA, indicating indecision. Sustained trading above 1,100 ₹ would confirm bullish continuation, while a breakdown below 1,060 ₹ could trigger weakness.

📉 RSI: At 42.8, RSI is neutral-to-weak, suggesting limited momentum and no strong oversold signal yet.

📉 MACD: Negative at -12.9, confirming bearish sentiment and lack of strong upward crossover.

📊 Bollinger Bands: Price is near the mid-to-lower band, reflecting consolidation with mild bearish bias.

📊 Volume Trends: Current volume (69,285) is below average weekly volume (77,294), showing reduced participation and cautious sentiment.

🎯 Momentum Signals: Weak short-term signals with bearish undertones. Consolidation near DMAs suggests indecision, awaiting stronger volume for breakout.

💹 Entry Zone: 1,050–1,065 ₹ (near 200 DMA support).

💹 Exit Zone: 1,110–1,130 ₹ (resistance near 50 DMA and trendline).

📌 Overall Trend: The stock is in a consolidation phase with bearish bias, awaiting stronger breakout confirmation.

Positive

• DII holdings increased by 1.01%, showing strong domestic institutional confidence.
• Debt-to-equity ratio of 0.02 indicates a nearly debt-free balance sheet.
• Dividend yield of 0.47% provides modest income appeal.

Limitation

• ROCE (2.91%) and ROE (1.04%) are very weak, reflecting poor efficiency.
• EPS of 1.15 ₹ is low compared to industry peers.
• Quarterly profit variation at -436% highlights severe earnings volatility.
• Stock P/E and PEG ratio are not meaningful due to negative earnings.

Company Negative News

• Quarterly PAT declined sharply to -48 Cr. from 4.1 Cr., showing significant earnings pressure.
• FII holdings decreased by 0.84%, reflecting reduced foreign investor confidence.

Company Positive News

• DII holdings increased, reflecting domestic support.
• Stock trading near long-term support levels, offering potential rebound opportunities.

Industry

• Industry PE at 30.6 is much higher than JUBLPHARMA’s effective valuation, suggesting peers are more attractively priced.
• Pharma sector benefits from global demand but faces margin pressures and regulatory challenges.

Conclusion

⚖️ JUBLPHARMA is consolidating near support levels with weak momentum and poor fundamentals. Entry around 1,050–1,065 ₹ offers defined risk, while exits near 1,110–1,130 ₹ are optimal. Long-term investors should be cautious due to earnings volatility and weak efficiency metrics, while short-term traders may find opportunities in technical rebounds.